No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
CN Stock MarketDetailed Quotes
300573 Shenyang Xingqi Pharmaceutical
- 259.58
- +1.41+0.55%
Market Closed Apr 30 15:00 CST
32.34BMarket Cap126.62P/E (TTM)
266.40High255.00Low20.94KlotVolume258.00Open258.17Pre Close547.19MTurnover2.19%Turnover Ratio134.71P/E (Static)124.59MShares266.6652wk High18.62P/B24.84BFloat Cap111.5252wk Low309.80Limit Up95.71MShs Float266.66Historical High206.54Limit Down4.42%Amplitude1.46Historical Low1.43Dividend TTM261.33Avg Price9.42KlotAsk0.55%Div YieldTTM100Lot Size9.62KlotBid
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Is Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Latest Stock Performance A Reflection Of Its Financial Health?
Most readers would already be aware that Shenyang Xingqi PharmaceuticalLtd's (SZSE:300573) stock increased significantly by 71% over the past three months. Given the company's impressive performance
Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80%
Shenyang Xingqi Pharmaceutical's (SHE:300573) attributable profit rose 80% to 34.7 million yuan in the first quarter from 19.3 million yuan in the year-ago period, according to a Friday filing with th
Sinqi Pharmaceutical (300573.SZ): Net profit of 347.48,900 yuan in the first quarter increased 79.59% year-on-year
Gelonghui, April 25 | Sinqi Pharmaceutical (300573.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 349.9 million yuan, up 22.10% year on year; net profit attributable to shareholders of listed companies was 347.489 million yuan, up 79.59% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 35.2409 million yuan, up 126.46% year on year; basic earnings per share were 0.28 yuan.
Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Sheds 3.4% This Week, as Yearly Returns Fall More in Line With Earnings Growth
We think all investors should try to buy and hold high quality multi-year winners. While the best companies are hard to find, but they can generate massive returns over long periods. Just think abou
Market Participants Recognise Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Revenues Pushing Shares 26% Higher
Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) shareholders would be excited to see that the share price has had a great month, posting a 26% gain and recovering from prior weakness. The ann
Changes in Hong Kong stocks | Okanvision Bio-B (01477) is now up more than 7% Sinqi Eye Medication Atropine Eye Drops Approved Clinical Trials of Listed Companies' Products Previously Approved
Okanvision Bio-B (01477) is now up more than 7%. As of press release, it is up 7.57% to HK$5.97, with a turnover of HK$10.8087 million.
Comments
The company's high P/S ratio is backed by strong forecasted revenue growth, outpacing the rest of the Pharmaceuticals industry. Investors anticipate this growth, justifying a higher stock price. A significant share price drop is unlikely under these conditions.
Market Participants Recognise Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Revenues Pushing Shares 26% Higher 2
Shenyang Xingqi Pharmaceutical's strong financials and high ROE hint at potential long-term stock value increase. Impressive net income growth and efficient earnings reinvestment suggest a positive outlook.
Despite Shenyang Xingqi Pharmaceutical Ltd's weak recent revenue performance, the high P/S ratio points to investors holding stocks, anticipating significant revenue recovery. But with forecasted growth mirrored by the industry, the current ratio may not be sustainable without improved performance.
Despite Shenyang Xingqi's lackluster revenue growth, the high P/S ratio implies investors are holding stocks in anticipation of a major revenue rebound. Yet, the expected revenue growth that matches with the industry's might not uphold this high P/S in the long run. An uplift in performance is necessary to justify this current ratio.
Shenyang Xingqi PharmaceuticalLtd's performance appears to be quite favorable, particularly due to high reinvestment of its profits leading to substantial earnings growth. Analysts are expecting the company to continue its recent growth streak.
Read more
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
%Chg